Skip to main content

Table 4 Clinical and immunological outcome

From: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

Patient Cycles received Off-therapy reason Off-study status PFS OS Immune response
1 2 P P 2 17 Neg
2 10 PSC NED 88 + 88 + Pos
3 6 R R 6.5 87 + Pos
4 4 P P 4 8 Pos
5 11 PSC R 13.5 30.5 Neg
6 18 PSC S 57 + 57 + Pos
  1. Abbreviations: P = progressive disease; R = recurrent disease; S = stable disease; NED = no evidence of disease; PSC = peptide stock completed; PFS = progression-free survival in months; OS = overall survival in months (both PFS and OS were calculated from the on-study date until progression, death, or last known follow-up marked as (+); Pos = positive immune response; Neg = negative immune response.